- 2.5 mg or 5 mg PO Daily; taken regardless of meals
- 2.5 mg PO Daily; if taking strong CYP450(3A4/5) inhibitors
- Safety and effectiveness in pediatric patients have not been established
Renal Dose Adjustment (Based on CrCl)
50 mL/min: 2.5 mg PO qdHepatic Dose Adjustment
Cautions: Use cautiously in
Onglyza interacts with :
Pregnancy Category:B
Breastfeeding: Safety unknown; data available on the use of drug during breastfeeding, prefer an alternate drug especially while nursing a newborn or preterm infant. This information is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 1 December 2010). Excreted in the milk of lactating rats. Manufacturer advises caution while using in nursing woman
US Trade Name(s)
US Availability
Onglyza
Canadian Trade Name(s)
Canadian Availability
UK Trade Name(s)
UK Availability
Australian Trade Name(s)
Australian Availability
Pricing data from www.DrugStore.com in U.S.A.
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.
Drug Name: Onglyza 2.5 MG Oral Tablet
Ingredient(s): Saxagliptin
Imprint: 2;5;4214
Color(s): Yellow
Shape: Round
Size (mm): 8.00
Score: 1
Inactive Ingredient(s): lactose monohydrate / cellulose, microcrystalline / croscarmellose sodium / magnesium stearate
Drug Label Author:
E.R. Squibb & Sons, L.L.C.
DEA Schedule:
Non-Scheduled
Drug Name: Onglyza 5 MG Oral Tablet
Ingredient(s): Saxagliptin
Imprint: 5;4215
Color(s): Pink
Shape: Round
Size (mm): 8.00
Score: 1
Inactive Ingredient(s): lactose monohydrate / cellulose, microcrystalline / croscarmellose sodium / magnesium stearate
Drug Label Author:
E.R. Squibb & Sons, L.L.C.
DEA Schedule:
Non-Scheduled
